MGMT-silenced, temozolomide-treated patients suffered recurrence after a longer time interval (14.9 versus 9.2 months, p = 0.02) and outside the radiation field, enforcing the role of MGMT gene methylation in glioblastoma prognosis [16]. This evidence concerns the gene MGMT and glioblastoma.